Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELYM Eliem Therapeutics	$2.38 +8.7%	$1.48	$2.35 ▼ $11.55	$70.81M	-0.39	486,688 shs	803,871 shs
INSY INSYS Therapeutics		$23,687,640.18	$0.14 ▼ $11.65	$21.71M	3.21	9.52 million shs	N/A
OSTX OS Therapies	$2.48 +3.3%	$1.83	$1.12 ▼ $7.00	$79.09M	N/A	737,634 shs	1.08 million shs
WHWK Whitehawk Therapeutics	$1.74 +5.5%	$1.83	$1.39 ▼ $3.81	$77.76M	0.55	102,761 shs	70,989 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELYM Eliem Therapeutics	-2.67%	+27.33%	+55.32%	+85.59%	-63.98%
INSY INSYS Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OSTX OS Therapies	+3.33%	+20.39%	+35.52%	+47.62%	-38.00%
WHWK Whitehawk Therapeutics	+5.45%	+8.75%	-13.43%	+173,999,900.00%	+173,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INSY INSYS Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.192 of 5 stars	3.6	0.0	0.0	0.0	2.2	0.8	0.6
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
INSY INSYS Therapeutics	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.25	Buy	$18.00	625.81% Upside
WHWK Whitehawk Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest INSY, WHWK, OSTX, and ELYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/11/2025	WHWK Whitehawk Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
INSY INSYS Therapeutics	$82.08M	0.00	N/A	N/A	($0.58) per share	0.00
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	$25.98M	3.16	N/A	N/A	$3.65 per share	0.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
INSY INSYS Therapeutics	-$124.51M	-$1.39	N/A	N/A	N/A	-346.61%	-1,430.37%	-64.04%	N/A
OSTX OS Therapies	-$7.79M	-$0.79	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
WHWK Whitehawk Therapeutics	-$63.69M	-$0.06	N/A	∞	N/A	99.42%	-75.99%	-68.57%	N/A

Latest INSY, WHWK, OSTX, and ELYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	WHWK Whitehawk Therapeutics	$0.49	-$0.76	-$1.25	-$0.76	$100.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
INSY INSYS Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELYM Eliem Therapeutics	N/A	60.41	60.41
INSY INSYS Therapeutics	N/A	0.54	0.50
OSTX OS Therapies	N/A	0.76	0.76
WHWK Whitehawk Therapeutics	N/A	20.41	20.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELYM Eliem Therapeutics	69.76%
INSY INSYS Therapeutics	14.93%
OSTX OS Therapies	N/A
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ELYM Eliem Therapeutics	4.70%
INSY INSYS Therapeutics	65.40%
OSTX OS Therapies	13.80%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
INSY INSYS Therapeutics	226	74.57 million	N/A	Optionable
OSTX OS Therapies	N/A	31.89 million	N/A	N/A
WHWK Whitehawk Therapeutics	40	47.13 million	23.61 million	N/A

INSY, WHWK, OSTX, and ELYM Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSY, WHWK, OSTX, and ELYM Company Descriptions

Eliem Therapeutics NASDAQ:ELYM

$2.38 +0.19 (+8.68%)

As of 08/22/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

INSYS Therapeutics NASDAQ:INSY

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

OS Therapies NYSE:OSTX

$2.48 +0.08 (+3.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.43 -0.05 (-2.18%)

As of 08/22/2025 07:31 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Whitehawk Therapeutics NASDAQ:WHWK

$1.74 +0.09 (+5.45%)

As of 08/22/2025 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time